ABOUT US Travere Therapeutics is a biopharmaceutical company whose mission is to identify, develop and deliver life-changing therapies to people living with rare disease. We stick by our values We are patient-inspired. We are courageous. We promote community. We are stronger together. And we pursue our vision of becoming a leading biopharmaceutical company dedicated to the delivery of innovation and hope to patients in the global rare disease community. OUR CULTURE We are impatient for the patients we serve. We are driven to deliver safe and effective therapies to patients as quickly as possible. To do this, we are advancing a pipeline of potential first-in-class medicines targeting rare diseases with significant unmet needs and oftentimes no approved treatment options. Our efforts are led by late-stage development programs of sparsentan, which is a novel product candidate targeting rare kidney diseases – focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). We are also partnering with leaders in patient advocacy and the National Institutes of Health (NIH) on earlier-stage development work in rare liver diseases. In addition, pegtibatinase (TVT-058), the first potential disease-modifying therapy for the treatment of classical homocystinuria (HCU), is in Phase 1/2 development. Today we aim to help patients with our four approved commercial therapies, Chenodal® (chenodiol), Cholbam® (cholic acid), Thiola® (tiopronin), and Thiola EC® (tiopronin) delayed-release tablets. We are committed to broad access for our FDA-approved therapies, and we provide personalized clinical support services through the Total Care Hub. We also sponsor diagnostic testing at no cost to qualified patients to help accurately diagnose a variety of disorders. Nonstop focus on people living with rare disease Because of our patient-centered purpose and recognition that rare disease has no borders, we supported the creation of the Rare Disease Network at Children’s National Rare Disease Institute (CNRDI). The network exists to improve rare disease care in the US and internationally through innovative digital medicine technology and partnerships with rare disease experts. In our commitment to support caregivers of people living with rare disease, we worked with NORD to establish the Rare Caregiver Respite Program, and with the National Alliance of Caregivers to better understand and help meet the needs of rare caregivers. We also supported the first-ever Diversity Inclusion Advocacy Fellowship at the EveryLife Foundation for Rare Diseases to increase the representative diversity of patient voices and to engage low income and minority communities in advocacy. Through our portfolio of approved products and our promising pipeline, we strive to help people achieve the best possible outcomes today and tomorrow. SENIOR LEADERSHIP BOARD OF DIRECTORS CULTURE CAREERS COVID-19 CONTACT US Pathfinder Travere Therapeutics to Present Abstracts at American Society of Nephrology Kidney Week 2021 SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present abstracts based on non-clinical data describing the potential for sparsentan, an investigational product candidate, to protect kidney function in models of rare glomerular diseases, including a potential anti-inflammatory role in IgA nephropathy (IgAN), at the American Society of Nephrology (ASN) Kidney Week 2021. Read the full press release > Travere Therapeutics Reports Third Quarter 2021 Financial Results and Organizational Progress SAN DIEGO, Oct. 28, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its third quarter 2021 financial results and provided a corporate update. Read the full press release > Jamela Diagnosed at birth with homocystinuria, Jamela reflects on what it was like growing up with this rare metabolic condition, and how her family continues to be a source of strength. Benji Benji, nine years old, loves wrestling with his father and playing with his best friends. He is quite fond of elevators – both watching them and riding in them. Benji is a happy kid. He is also a rare kid, and lives with NGLY1 deficiency, a complex neurological syndrome resulting from a shortage of the enzyme N-glycanase 1. Read about Benji’s ultrarare journey, Travere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe, Australia and New Zealand SAN DIEGO and ST GALLEN, Switzerland, Sept. 15, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) and Vifor Pharma today announced the companies have entered into a joint collaboration and licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand. Sparsentan is a novel investigational product candidate currently being evaluated in pivotal Phase 3 clinical studies for the treatment of FSGS and IgAN, two rare progressive kidney disorders and leading causes of end-stage kidney disease. There are currently no approved medicines indicated for FSGS or IgAN. Sparsentan has been granted Orphan Drug Designation for the treatment of FSGS and IgAN in the U.S. and Europe. Read the full press release > Travere Therapeutics Appoints Ruth Williams-Brinkley to its Board of Directors SAN DIEGO, Sept. 14, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the appointment of Ruth Williams-Brinkley to the Company’s Board of Directors, effective immediately. Ms. Williams-Brinkley brings to Travere more than 35 years of executive leadership in care delivery and health plan operations. Read the full press release > RET153 © 2021 Travere Therapeutics, Inc. All rights reserved. For US audiences. Chenodal®, Cholbam® and Total Care HUB® are registered trademarks of Travere Therapeutics, Inc. Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company. Terms and Conditions | Privacy Policies | Cookie Preferences This website uses cookies for optimal site functionality. By continuing to use this website, you consent to our use of cookies. To change your cookie preferences, click on "Cookie Settings" or for more information, please see ourPrivacy Policies. Accept All Cookies Cookie Settings